ApoB antibody
- Known as:
- ApoB (anti-)
- Catalog number:
- 10-1840
- Product Quantity:
- 200 ul
- Category:
- -
- Supplier:
- Fitzgerald
- Gene target:
- ApoB antibody
Related genes to: ApoB antibody
- Gene:
- APOB NIH gene
- Name:
- apolipoprotein B
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 2p24.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-10-05
Related products to: ApoB antibody
Related articles to: ApoB antibody
- Reverse cascade genetic screening, following initial lipid testing, is an effective strategy for the early diagnosis of familial hypercholesterolemia (FH) and related hereditary dyslipidemias. In this study, we present the results of a pilot project in Russia. - Source: PubMed
Miroshnikova Valentina VIzyumchenko Artem DSmirnova Nataliia NKuprienko Natalia BUrazgildeeva Soreiia AGrunina Maria NLinkova Svetlana VDracheva Kseniia VTanayants Kseniia OPetrik Alina AGlotov Oleg SLegostaeva Kristina VKulikov Alexandr NIlyinets Irina VIvashikina Tat'yana MKlochko Lidiya APchelina Sofya N - Multiple low-density lipoprotein cholesterol (LDL-C) equations can be applied to every standard lipid panel. Disagreement across a treatment threshold may indicate unstable classification. - Source: PubMed
Publication date: 2026/09/14
Doku RonaldOsafo Nana Yaw AKwagyan JohnSoutherland William M - Cardiometabolic diseases-principally cardiovascular disease, type 2 diabetes, and obesity-remain leading global drivers of premature mortality, disability, and healthcare expenditure, despite substantial advances in their biological understanding, risk assessment, and treatment. This narrative review critically examines why increasingly effective preventive interventions have failed to yield a commensurate reduction in population-level disease burden, identifying the biological, clinical, organizational, economic, and social factors that sustain this evidence-to-practice gap. It integrates evidence across three complementary dimensions: (1) The biological continuum, linking metabolic dysfunction, chronic low-grade inflammation, and cumulative exposure to apolipoprotein B (ApoB)-containing lipoproteins with atherosclerotic cardiovascular disease; (2) The clinical continuum, extending from early risk recognition and targeted diagnostic evaluation to individualized intervention and longitudinal reassessment; and (3) The organizational continuum, required to deliver coordinated, multidisciplinary prevention across health systems. Particular attention is given to total and lifetime cardiovascular risk, the clinical application and limitations of SCORE2 and SCORE2-OP, and the diagnostic challenges of identifying younger or apparently healthy individuals whose low short-term risk masks significant cumulative lifetime exposure. The review critically evaluates the causal role and clinical interpretation of ApoB-containing lipoproteins, including lipoprotein(a) [Lp(a)], and the complementary role of emerging biomarkers and subclinical atherosclerosis imaging, while carefully distinguishing enhanced risk prediction from demonstrated improvements in hard clinical outcomes. An educational and translational clinical vignette illustrates how the longitudinal interpretation of routine clinical and laboratory data supports proportionate assessment of persistent dyslipidemia, treatment response, and plausible primary and secondary contributors to cardiometabolic risk well before symptom onset. Rather than attributing borderline abnormalities to a single occult disorder, the vignette demonstrates how standardized confirmation, verification of medication exposure, etiological assessment, targeted referral, and structured reassessment can translate routine data into actionable preventive pathways. Ultimately, this analysis indicates that cardiometabolic prevention is constrained less by a lack of scientific evidence or effective pharmacotherapies than by delayed risk recognition, therapeutic inertia, poor treatment adherence, fragmented care pathways, limited multidisciplinary coordination, structural health inequalities, and the incomplete integration of clinical, laboratory, behavioral, environmental, and patient-reported data. Improving outcomes therefore demands a systemic shift from episodic, disease-specific management toward early, lifelong, proportionate, coordinated, equitable, and patient-centered cardiometabolic prevention-underpinned by implementation science, precision prevention, digital health solutions, health-economic evaluations, patient-reported outcome measures (PROMs), and patient-reported experience measures (PREMs). - Source: PubMed
Publication date: 2026/09/14
Krzyściak WirginiaLatacz PawełChwała MaciejLizoń AnnaTrofimiuk-Müldner Małgorzata - To investigate the association between risk-weighted apolipoprotein B (RW-apoB) levels and prevalent kidney stones. - Source: PubMed
Publication date: 2026/09/14
Chen XiaogangShen XinLiu MengweiLiu YiZhang QiankunXu HaoZhang Xiansheng - - Source: PubMed
Publication date: 2026/09/28
Mahmoud Dr Randa Salah Gomaa